Fig. 7: Efficacy of EGFR-TKIs in LUAD, ASC, and LUSC.
From: Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma
Kaplan–Meier curves estimate the progression-free survival of a LUAD, ASC, and LUSC treated with EGFR-TKIs, b resected ASC with evaluable SCC proportion above and below 50% upon EGFR-TKI treatment, c LUAD, ASC, and LUSC patients with EGFR exon-19 deletion receiving first-generation EGFR-TKIs as first-line treatment, and d LUAD, ASC, and LUSC patients with EGFR L858R on receiving first-generation EGFR-TKIs as first-line treatment. Two-sided P values were calculated using the log-rank test.
